Bicycle Therapeutics (BCYC) Income towards Parent Company: 2018-2025
Historic Income towards Parent Company for Bicycle Therapeutics (BCYC) over the last 8 years, with Sep 2025 value amounting to -$59.1 million.
- Bicycle Therapeutics' Income towards Parent Company fell 16.33% to -$59.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$256.4 million, marking a year-over-year decrease of 53.84%. This contributed to the annual value of -$174.8 million for FY2024, which is 3.49% up from last year.
- As of Q3 2025, Bicycle Therapeutics' Income towards Parent Company stood at -$59.1 million, which was up 25.14% from -$79.0 million recorded in Q2 2025.
- Over the past 5 years, Bicycle Therapeutics' Income towards Parent Company peaked at -$14.7 million during Q3 2021, and registered a low of -$79.0 million during Q2 2025.
- In the last 3 years, Bicycle Therapeutics' Income towards Parent Company had a median value of -$49.9 million in 2023 and averaged -$50.4 million.
- In the last 5 years, Bicycle Therapeutics' Income towards Parent Company surged by 32.13% in 2024 and then slumped by 129.10% in 2025.
- Bicycle Therapeutics' Income towards Parent Company (Quarterly) stood at -$19.1 million in 2021, then plummeted by 94.02% to -$37.0 million in 2022, then crashed by 34.01% to -$49.6 million in 2023, then declined by 16.31% to -$57.6 million in 2024, then fell by 16.33% to -$59.1 million in 2025.
- Its last three reported values are -$59.1 million in Q3 2025, -$79.0 million for Q2 2025, and -$60.7 million during Q1 2025.